Skip to main content
Erschienen in: Diabetologia 11/2010

01.11.2010 | Article

Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor

verfasst von: K. C. Sourris, A. L. Morley, A. Koitka, P. Samuel, M. T. Coughlan, S. A. Penfold, M. C. Thomas, A. Bierhaus, P. P. Nawroth, H. Yamamoto, T. J. Allen, T. Walther, T. Hussain, M. E. Cooper, J. M. Forbes

Erschienen in: Diabetologia | Ausgabe 11/2010

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The receptor for AGEs (RAGE) contributes to the development and progression of diabetic nephropathy. In this study, we examined whether the protective effects of RAGE blockade are exerted via modulation of the renal angiotensin II type 2 (AT2) receptor.

Methods

Control and streptozotocin diabetic mice, wild-type or deficient in the AT2 receptor (At2 knockout [KO]) or RAGE (Rage KO), were studied for 24 weeks. Adenoviral overexpression of full-length Rage in primary rat mesangial cells was also used to determine the effects on AT2 production.

Results

With diabetes, Rage-deficient mice had less albuminuria, and an attenuation of hyperfiltration and glomerulosclerosis as compared with diabetic wild-type and At2 KO mice. Renal gene and protein expression of RAGE was elevated with diabetes. Diabetic Rage KO mice had a greater increase in renal AT2 receptor protein than was seen in diabetic wild-type mice. Diabetes-induced increases in renal cytosolic and mitochondrial superoxide generation were prevented in diabetic Rage KO mice, but enhanced in all At2 KO mice. Adenoviral overexpression of RAGE or AGE treatment decreased cell surface AT2 expression, in association with increasing superoxide generation; both were reversed using antioxidants N-acetylcysteine and apocynin, and soluble RAGE in primary mesangial cells.

Conclusions/interpretation

RAGE appears to be a common and key modulator of AT2 receptor expression, a finding that would implicate a newly defined RAGE–AT2 axis in the development and progression of diabetic nephropathy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ (1993) Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 268:24539–24542PubMed Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ (1993) Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 268:24539–24542PubMed
2.
Zurück zum Zitat Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE (1991) Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 351:233–236CrossRefPubMed Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE (1991) Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 351:233–236CrossRefPubMed
3.
Zurück zum Zitat Ribeiro-Oliveira A Jr, Nogueira AI, Pereira RM, Boas WW, Dos Santos RA, Simoes e Silva AC (2008) The renin–angiotensin system and diabetes: an update. Vasc Health Risk Manag 4:787–803PubMed Ribeiro-Oliveira A Jr, Nogueira AI, Pereira RM, Boas WW, Dos Santos RA, Simoes e Silva AC (2008) The renin–angiotensin system and diabetes: an update. Vasc Health Risk Manag 4:787–803PubMed
4.
Zurück zum Zitat Morrissey JJ, Klahr S (1999) Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis. Am J Physiol 276:F39–F45PubMed Morrissey JJ, Klahr S (1999) Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis. Am J Physiol 276:F39–F45PubMed
5.
Zurück zum Zitat Ma J, Nishimura H, Fogo A, Kon V, Inagami T, Ichikawa I (1998) Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int 53:937–944CrossRefPubMed Ma J, Nishimura H, Fogo A, Kon V, Inagami T, Ichikawa I (1998) Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int 53:937–944CrossRefPubMed
6.
Zurück zum Zitat Arima S, Endo Y, Yaoita H et al (1997) Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole. J Clin Invest 100:2816–2823CrossRefPubMed Arima S, Endo Y, Yaoita H et al (1997) Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole. J Clin Invest 100:2816–2823CrossRefPubMed
7.
Zurück zum Zitat van Esch JH, Schuijt MP, Sayed J, Choudhry Y, Walther T, Jan Danser AH (2006) AT2 receptor-mediated vasodilation in the mouse heart depends on AT1A receptor activation. Br J Pharmacol 148:452–458CrossRefPubMed van Esch JH, Schuijt MP, Sayed J, Choudhry Y, Walther T, Jan Danser AH (2006) AT2 receptor-mediated vasodilation in the mouse heart depends on AT1A receptor activation. Br J Pharmacol 148:452–458CrossRefPubMed
8.
Zurück zum Zitat Miyazaki M, Takai S (2006) Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase. J Pharmacol Sci 100:391–397CrossRefPubMed Miyazaki M, Takai S (2006) Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase. J Pharmacol Sci 100:391–397CrossRefPubMed
9.
Zurück zum Zitat Wolf G (2004) New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest 34:785–796CrossRefPubMed Wolf G (2004) New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest 34:785–796CrossRefPubMed
10.
Zurück zum Zitat UK Prospective Diabetes Study group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317:703–713 UK Prospective Diabetes Study group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317:703–713
11.
Zurück zum Zitat Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456–1462CrossRefPubMed Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456–1462CrossRefPubMed
12.
Zurück zum Zitat Brenner BM, Cooper ME, de Zeeuw D et al (2000) The losartan renal protection study—rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 1:328–335CrossRefPubMed Brenner BM, Cooper ME, de Zeeuw D et al (2000) The losartan renal protection study—rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 1:328–335CrossRefPubMed
13.
Zurück zum Zitat Brenner BM, Cooper ME, de Zeeuw D et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869CrossRefPubMed Brenner BM, Cooper ME, de Zeeuw D et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869CrossRefPubMed
14.
Zurück zum Zitat Mogensen CE, Neldam S, Tikkanen I et al (2000) Randomised controlled trial of dual blockade of renin–angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321:1440–1444CrossRefPubMed Mogensen CE, Neldam S, Tikkanen I et al (2000) Randomised controlled trial of dual blockade of renin–angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321:1440–1444CrossRefPubMed
15.
Zurück zum Zitat Mauer M, Zinman B, Gardiner R et al (2009) Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361:40–51CrossRefPubMed Mauer M, Zinman B, Gardiner R et al (2009) Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361:40–51CrossRefPubMed
16.
Zurück zum Zitat Bilous R, Chaturvedi N, Sjolie AK et al (2009) Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 151:11–20PubMed Bilous R, Chaturvedi N, Sjolie AK et al (2009) Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 151:11–20PubMed
17.
Zurück zum Zitat Flyvbjerg A, Denner L, Schrijvers BF et al (2004) Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 53:166–172CrossRefPubMed Flyvbjerg A, Denner L, Schrijvers BF et al (2004) Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 53:166–172CrossRefPubMed
18.
Zurück zum Zitat Coughlan MT, Thorburn DR, Penfold SA et al (2009) RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 20:742–752CrossRefPubMed Coughlan MT, Thorburn DR, Penfold SA et al (2009) RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 20:742–752CrossRefPubMed
19.
Zurück zum Zitat Myint KM, Yamamoto Y, Doi T et al (2006) RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 55:2510–2522CrossRefPubMed Myint KM, Yamamoto Y, Doi T et al (2006) RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 55:2510–2522CrossRefPubMed
20.
Zurück zum Zitat Yamamoto Y, Kato I, Doi T et al (2001) Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108:261–268PubMed Yamamoto Y, Kato I, Doi T et al (2001) Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108:261–268PubMed
21.
Zurück zum Zitat Inagi R, Yamamoto Y, Nangaku M et al (2006) A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in RAGE/iNOS transgenic mice. Diabetes 55:356–366CrossRefPubMed Inagi R, Yamamoto Y, Nangaku M et al (2006) A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in RAGE/iNOS transgenic mice. Diabetes 55:356–366CrossRefPubMed
22.
Zurück zum Zitat Forbes JM, Thorpe SR, Thallas-Bonke V et al (2005) Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 16:2363–2372CrossRefPubMed Forbes JM, Thorpe SR, Thallas-Bonke V et al (2005) Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 16:2363–2372CrossRefPubMed
23.
Zurück zum Zitat Miyata T, van Ypersele de Strihou C, Ueda Y et al (2002) Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 13:2478–2487CrossRefPubMed Miyata T, van Ypersele de Strihou C, Ueda Y et al (2002) Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 13:2478–2487CrossRefPubMed
24.
Zurück zum Zitat Nakamura K, Yamagishi S, Nakamura Y et al (2005) Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res 70:137–141CrossRefPubMed Nakamura K, Yamagishi S, Nakamura Y et al (2005) Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res 70:137–141CrossRefPubMed
25.
Zurück zum Zitat Forbes JM, Thomas MC, Thorpe SR, Alderson NL, Cooper ME (2004) The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. Kidney Int Suppl:S105–S107 Forbes JM, Thomas MC, Thorpe SR, Alderson NL, Cooper ME (2004) The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. Kidney Int Suppl:S105–S107
26.
Zurück zum Zitat Thomas MC, Tikellis C, Burns WM et al (2005) Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 16:2976–2984CrossRefPubMed Thomas MC, Tikellis C, Burns WM et al (2005) Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 16:2976–2984CrossRefPubMed
27.
Zurück zum Zitat Ruster C, Bondeva T, Franke S, Tanaka N, Yamamoto H, Wolf G (2009) Angiotensin II upregulates RAGE expression on podocytes: role of AT2 receptors. Am J Nephrol 29:538–550CrossRefPubMed Ruster C, Bondeva T, Franke S, Tanaka N, Yamamoto H, Wolf G (2009) Angiotensin II upregulates RAGE expression on podocytes: role of AT2 receptors. Am J Nephrol 29:538–550CrossRefPubMed
28.
Zurück zum Zitat Coughlan MT, Thallas-Bonke V, Pete J et al (2007) Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? Endocrinology 148:886–895CrossRefPubMed Coughlan MT, Thallas-Bonke V, Pete J et al (2007) Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? Endocrinology 148:886–895CrossRefPubMed
29.
Zurück zum Zitat Ichiki T, Labosky PA, Shiota C et al (1995) Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 377:748–750CrossRefPubMed Ichiki T, Labosky PA, Shiota C et al (1995) Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 377:748–750CrossRefPubMed
30.
Zurück zum Zitat Bierhaus A, Haslbeck KM, Humpert PM et al (2004) Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest 114:1741–1751PubMed Bierhaus A, Haslbeck KM, Humpert PM et al (2004) Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest 114:1741–1751PubMed
31.
Zurück zum Zitat Constien R, Forde A, Liliensiek B et al (2001) Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis 30:36–44CrossRefPubMed Constien R, Forde A, Liliensiek B et al (2001) Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis 30:36–44CrossRefPubMed
32.
Zurück zum Zitat Forbes JM, Cooper ME, Thallas V et al (2002) Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51:3274–3282CrossRefPubMed Forbes JM, Cooper ME, Thallas V et al (2002) Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51:3274–3282CrossRefPubMed
33.
Zurück zum Zitat Dunn SR, Qi Z, Bottinger EP, Breyer MD, Sharma K (2004) Utility of endogenous creatinine clearance as a measure of renal function in mice. Kidney Int 65:1959–1967CrossRefPubMed Dunn SR, Qi Z, Bottinger EP, Breyer MD, Sharma K (2004) Utility of endogenous creatinine clearance as a measure of renal function in mice. Kidney Int 65:1959–1967CrossRefPubMed
34.
Zurück zum Zitat Thallas-Bonke V, Thorpe SR, Coughlan MT et al (2008) Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 57:460–469CrossRefPubMed Thallas-Bonke V, Thorpe SR, Coughlan MT et al (2008) Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 57:460–469CrossRefPubMed
35.
Zurück zum Zitat Fukami K, Ueda S, Yamagishi S et al (2004) AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 66:2137–2147CrossRefPubMed Fukami K, Ueda S, Yamagishi S et al (2004) AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 66:2137–2147CrossRefPubMed
36.
Zurück zum Zitat Benndorf RA, Krebs C, Hirsch-Hoffmann B et al (2009) Angiotensin II type 2 receptor deficiency aggravates renal injury and reduces survival in chronic kidney disease in mice. Kidney Int 75:1039–1049CrossRefPubMed Benndorf RA, Krebs C, Hirsch-Hoffmann B et al (2009) Angiotensin II type 2 receptor deficiency aggravates renal injury and reduces survival in chronic kidney disease in mice. Kidney Int 75:1039–1049CrossRefPubMed
37.
Zurück zum Zitat Breyer MD, Bottinger E, Brosius FC 3rd et al (2005) Mouse models of diabetic nephropathy. J Am Soc Nephrol 16:27–45CrossRefPubMed Breyer MD, Bottinger E, Brosius FC 3rd et al (2005) Mouse models of diabetic nephropathy. J Am Soc Nephrol 16:27–45CrossRefPubMed
38.
Zurück zum Zitat Freeman HC, Hugill A, Dear NT, Ashcroft FM, Cox RD (2006) Deletion of nicotinamide nucleotide transhydrogenase: a new quantitive trait locus accounting for glucose intolerance in C57BL/6J mice. Diabetes 55:2153–2156CrossRefPubMed Freeman HC, Hugill A, Dear NT, Ashcroft FM, Cox RD (2006) Deletion of nicotinamide nucleotide transhydrogenase: a new quantitive trait locus accounting for glucose intolerance in C57BL/6J mice. Diabetes 55:2153–2156CrossRefPubMed
39.
Zurück zum Zitat Ding G, Zhang A, Huang S et al (2007) ANG II induces c-Jun NH2-terminal kinase activation and proliferation of human mesangial cells via redox-sensitive transactivation of the EGFR. Am J Physiol Renal Physiol 293:F1889–F1897CrossRefPubMed Ding G, Zhang A, Huang S et al (2007) ANG II induces c-Jun NH2-terminal kinase activation and proliferation of human mesangial cells via redox-sensitive transactivation of the EGFR. Am J Physiol Renal Physiol 293:F1889–F1897CrossRefPubMed
40.
Zurück zum Zitat Tsang SW, Ip SP, Leung PS (2004) Prophylactic and therapeutic treatments with AT 1 and AT 2 receptor antagonists and their effects on changes in the severity of pancreatitis. Int J Biochem Cell Biol 36:330–339CrossRefPubMed Tsang SW, Ip SP, Leung PS (2004) Prophylactic and therapeutic treatments with AT 1 and AT 2 receptor antagonists and their effects on changes in the severity of pancreatitis. Int J Biochem Cell Biol 36:330–339CrossRefPubMed
41.
Zurück zum Zitat Siragy HM, Carey RM (1999) Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension 33:1237–1242PubMed Siragy HM, Carey RM (1999) Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension 33:1237–1242PubMed
42.
Zurück zum Zitat Siragy HM, Carey RM (1997) The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 100:264–269CrossRefPubMed Siragy HM, Carey RM (1997) The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 100:264–269CrossRefPubMed
43.
Zurück zum Zitat Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL (2001) Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280:E685–E694PubMed Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL (2001) Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280:E685–E694PubMed
44.
Zurück zum Zitat Forbes JM, Coughlan MT, Cooper ME (2008) Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57:1446–1454CrossRefPubMed Forbes JM, Coughlan MT, Cooper ME (2008) Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57:1446–1454CrossRefPubMed
45.
Zurück zum Zitat Siragy HM, Inagami T, Ichiki T, Carey RM (1999) Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci U S A 96:6506–6510CrossRefPubMed Siragy HM, Inagami T, Ichiki T, Carey RM (1999) Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci U S A 96:6506–6510CrossRefPubMed
46.
Zurück zum Zitat Saavedra JM, Hauser W, Ciuffo G et al (2001) Increased AT(1) receptor expression and mRNA in kidney glomeruli of AT(2) receptor gene-disrupted mice. Am J Physiol Renal Physiol 280:F71–F78PubMed Saavedra JM, Hauser W, Ciuffo G et al (2001) Increased AT(1) receptor expression and mRNA in kidney glomeruli of AT(2) receptor gene-disrupted mice. Am J Physiol Renal Physiol 280:F71–F78PubMed
47.
Zurück zum Zitat Siragy HM, Carey RM (1997) The subtype 2 angiotensin receptor regulates renal prostaglandin F2 alpha formation in conscious rats. Am J Physiol 273:R1103–R1107PubMed Siragy HM, Carey RM (1997) The subtype 2 angiotensin receptor regulates renal prostaglandin F2 alpha formation in conscious rats. Am J Physiol 273:R1103–R1107PubMed
48.
Zurück zum Zitat Wang H, Gallinat S, Li HW, Sumners C, Raizada MK, Katovich MJ (2004) Elevated blood pressure in normotensive rats produced by ‘knockdown’ of the angiotensin type 2 receptor. Exp Physiol 89:313–322CrossRefPubMed Wang H, Gallinat S, Li HW, Sumners C, Raizada MK, Katovich MJ (2004) Elevated blood pressure in normotensive rats produced by ‘knockdown’ of the angiotensin type 2 receptor. Exp Physiol 89:313–322CrossRefPubMed
49.
Zurück zum Zitat Li Z, Iwai M, Wu L et al (2003) Role of AT2 receptor in the brain in regulation of blood pressure and water intake. Am J Physiol Heart Circ Physiol 284:H116–H121PubMed Li Z, Iwai M, Wu L et al (2003) Role of AT2 receptor in the brain in regulation of blood pressure and water intake. Am J Physiol Heart Circ Physiol 284:H116–H121PubMed
Metadaten
Titel
Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor
verfasst von
K. C. Sourris
A. L. Morley
A. Koitka
P. Samuel
M. T. Coughlan
S. A. Penfold
M. C. Thomas
A. Bierhaus
P. P. Nawroth
H. Yamamoto
T. J. Allen
T. Walther
T. Hussain
M. E. Cooper
J. M. Forbes
Publikationsdatum
01.11.2010
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 11/2010
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1837-2

Weitere Artikel der Ausgabe 11/2010

Diabetologia 11/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.